qxnews

To view this email as a web page, click here

This week's sponsor is Premier Research.
	>From Lab to Bedside: The Latest Rare Oncology Drug Research Study of rare cancers demands immersion in dual indications where strategies often don't mesh. Attend our Feb. 28 webinar for fresh insights on speeding development of new drugs. Register now. Premier Research. It's what we do. Best.

Today's Rundown

Featured Story

Lilly to ax 200 R&D positions globally

February 6, 2017 | By Nick Paul Taylor

Eli Lilly is working to cut 200 R&D positions. The Big Pharma is framing the action as a “voluntary reallocation program” that will see it reduce its global R&D headcount by nearly 3% while it ups its investment in other areas.

This week's sponsor is Medidata.
	[Webinar] What Errors Are Lurking in Your Trial Data? Tuesday, February 28 \| 12pm ET / 9am PT What errors are lurking in your trial data? Most data monitoring only identifies risks your team knows to look for. Learn how machine learning saves time and money, and more importantly, saves your trial from poor data. Reserve Your Spot Today!

BMS, Innate checkpoint inhibitor flunks AML phase 2

Monday, February 6, 2017

A phase 2 trial of Innate Pharma’s lirilumab in elderly patients with acute myeloid leukemia (AML) has missed its primary endpoint. The Bristol-Myers Squibb-partnered checkpoint inhibitor failed to improve leukemia-free survival by more than placebo.

Startup Chondrial in $22.6M Series A, gains new CEO, ataxia med

Monday, February 6, 2017

Chondrial Therapeutics has secured a near $23 million raise, led by VC Deerfield Management, and has taken on Deerfield’s adviser Carole Ben-Maimon as its new president and CEO.

Ablynx files rare blood disorder drug, raising prospect of first commercial product next year

Monday, February 6, 2017

Belgian biotech Ablynx has filed its first-ever marketing application, seeking EU approval for its new drug for an ultrarare blood clotting disorder.

Acquisitive LabCorp in $8B PPD play: Reuters

Monday, February 6, 2017

Medical testing company LabCorp is prepared to spend $8 billion on one of the largest CROs in the world, coming hot on the heels of it buying up New Jersey-headquartered Covance in an acquisition worth just over $6 billion in 2015.

Pharma sits on sidelines for Super Bowl LI, but one DTC parody grabs the spotlight

Monday, February 6, 2017

Pharma companies sat out the Super Bowl this year after last year’s intense scrutiny—and criticism—of three ads that aired. But their DTC devices did make one appearance.

News of Note

Strata Oncology will work with Epizyme to help support trials of its troubled blood cancer med tazemetostat. Release

BioTime has boosted its ophthalmology portfolio with a licensing deal for a next-gen retinal disease med out of the University of Pittsburgh Medical Center. Statement

Amid the $5.2 billion buyout deal from Takeda, Ariad said it has submitted an app to the EMA for its blood cancer candidate brigatinib. Release

Events

CBI’s Abuse Deterrent Formulations Summit

March 7-8, 2017 | Alexandria, VA

PEGS: The Essential Protein Engineering Summit

May 1-5, 2017 | Boston, MA

Drug Development Boot Camp® 2017

November 15-16, 2017 | Boston, MA

BIO CEO & Investor Conference

February 13 – 14, 2017 | The Waldorf Astoria, New York, NY

Today's Rundown

Featured Story

Lilly to ax 200 R&D positions globally

Top Stories

BMS, Innate checkpoint inhibitor flunks AML phase 2

Startup Chondrial in $22.6M Series A, gains new CEO, ataxia med

Ablynx files rare blood disorder drug, raising prospect of first commercial product next year

Acquisitive LabCorp in $8B PPD play: Reuters

Pharma sits on sidelines for Super Bowl LI, but one DTC parody grabs the spotlight

News of Note

Resources

[Whitepaper] Expert Advice: Designing Systems for Global Content Processes

[Whitepaper] Delayed and Confusing IDMP Requirements Demand Two-Part Strategy

[Whitepaper] Transformation Initiatives Underway for Regulatory Information Management

[Whitepaper] Considering an eTMF Solution? Industry Research Reveals the Top Benefits

[Whitepaper] The Trailblazer's Guide to Apps

[Whitepaper] Ensuring the Greatest Return From Your Poorly Soluble Molecule

Events